Cibus, Inc. (NASDAQ:CBUS – Get Free Report) EVP Gregory Francis William Gocal sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $10.00, for a total transaction of $20,000.00. Following the completion of the transaction, the executive vice president now owns 316,844 shares of the company’s stock, valued at $3,168,440. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Gregory Francis William Gocal also recently made the following trade(s):
- On Thursday, June 27th, Gregory Francis William Gocal sold 2,000 shares of Cibus stock. The stock was sold at an average price of $10.00, for a total transaction of $20,000.00.
Cibus Price Performance
CBUS stock traded up $0.43 during trading on Monday, reaching $10.37. 127,204 shares of the company were exchanged, compared to its average volume of 106,308. The company has a 50-day moving average of $12.50 and a two-hundred day moving average of $16.21. The company has a market capitalization of $223.47 million, a price-to-earnings ratio of -0.57 and a beta of 1.91. Cibus, Inc. has a twelve month low of $7.41 and a twelve month high of $24.61.
Institutional Investors Weigh In On Cibus
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Cibus by 3.7% during the 1st quarter. Vanguard Group Inc. now owns 721,945 shares of the company’s stock worth $16,215,000 after acquiring an additional 26,017 shares during the last quarter. Indie Asset Partners LLC boosted its stake in shares of Cibus by 30.1% in the 4th quarter. Indie Asset Partners LLC now owns 16,929 shares of the company’s stock valued at $332,000 after purchasing an additional 3,921 shares during the last quarter. Blue Trust Inc. bought a new stake in shares of Cibus in the 4th quarter valued at $301,000. Cerity Partners LLC bought a new stake in shares of Cibus in the 4th quarter valued at $323,000. Finally, Citigroup Inc. bought a new stake in shares of Cibus in the 3rd quarter valued at $199,000. 33.81% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Cibus in a research report on Friday, May 10th.
Check Out Our Latest Stock Report on Cibus
Cibus Company Profile
Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Recommended Stories
- Five stocks we like better than Cibus
- What is a Low P/E Ratio and What Does it Tell Investors?
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- How to invest in blue chip stocks
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- 3 Warren Buffett Stocks to Buy Now
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.